On July 11, 2025, Helix Acquisition Corp. II announced that the SEC declared effective its Registration Statement for a planned business combination with TheRas, Inc., which will rename the company to BridgeBio Oncology Therapeutics after closing. This event is significant as it marks a major step towards the merger between the two companies.